生物制药公司Metavia近日宣布，其针对肥胖症治疗的GLP-1与胰高血糖素双靶点激动剂Da-1726已完成高剂量组一期临床试验的首例患者给药。该研究旨在评估药物在提升剂量水平下的安全性与耐受性，标志着这款代谢疾病疗法开发取得重要阶段性进展。Da-1726通过同时激活GLP-1和胰高血糖素受体，有望在控制血糖的同时增强能量消耗，为肥胖治疗提供新机制方向。
生物制药公司Metavia近日宣布，其针对肥胖症治疗的GLP-1与胰高血糖素双靶点激动剂Da-1726已完成高剂量组一期临床试验的首例患者给药。该研究旨在评估药物在提升剂量水平下的安全性与耐受性，标志着这款代谢疾病疗法开发取得重要阶段性进展。Da-1726通过同时激活GLP-1和胰高血糖素受体，有望在控制血糖的同时增强能量消耗，为肥胖治疗提供新机制方向。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.